In prostate cancer, we're using combinations by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, MD Anderson Cancer Center.
In prostate cancer, combination therapies are being used to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy, said Sumit Subudhi, MD, PhD, genitourinary medical oncology, Cancer Medicine, MD Anderson Cancer Center.
Transcript (slightly modified)
Prostate cancer has had lower response rates to single-agent immune checkpoint inhibitors than other cancers. How are you working towards understanding who will have the best response to these inhibitors?
It’s been a real struggle to get the response we see in malignancies such as melanoma, kidney, and bladder. What we’re starting to understand is that the prostate cancer tumor microenvironment is just really an immunosuppressive 1, and so the strategies we’re using now is using combinations, and rational combinations, by looking to see how 1 drug may trigger an immune infiltrate or proteins that allow the tumor to resist the monotherapy.
So, for example we’ve completed a trial where we were doing ipilimumab plus anti- PD-1, and the reason for that was after giving 2 doses of ipilimumab, we found that the tumor microenvironment upregulates both PD-1 and PD-L1, so by doing the combination, we should see better responses, and so far it looks like the early signals show that. We’re getting better response, but not as well as we see in melanoma.
What we’re going to have to do is find out who are these patients that actually respond so that we can enrich that population and then also better understand why the other patients are not responding.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More